Anonymous pumpers trying to spell it all out for the company isn't going to make a difference. Only management and their analyst can do that. Noticeably all missing, btw. The stock will go nowhere on approval without it feeling like a real company with real management.
What's L's claim going to be that a patient still needs to take chemo / rad but should gain an extra three months on average -maybe? And, what's to stop patients from participating in other L combo trials instead of going with commercialized L? Not even getting into the fact they're broke, there are a million investor questions that should've already been answered but instead just silence.